Sign in
Active, not recruitingPhase 2

Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH)

Key facts

Who runs it
Johns Hopkins University
Where
Albuquerque, Baltimore, Birmingham, Brooklyn, Cincinnati, Houston, Lexington, New Haven, Palo Alto, San Antonio, and Stuart, United StatesSee the 11 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
120 people, planned
Started
10 Oct 2022
Expected to end
1 Oct 2027
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MW189
  • Saline
Record updated
2 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Confirmed diagnosis of spontaneous, non-traumatic ICH
  • 10 mL ≤ ICH ≤ 60 mL (confirmed via diagnostic and stability CT scans utilizing volumetric assessment)
  • Participants receiving anticoagulants are eligible upon reversal and stability within 24hrs after onset of ICH symptoms
  • Age ≥ 18 years
  • Able to receive first dose of test article ≤ 24h after onset of ICH symptoms
  • NIHSS score ≥ 2 at randomization or Glasgow Coma Scale ≥ 5 at randomization
  • Controlled blood pressure (systolic BP < 180 mm Hg) at randomization
  • Premorbid magnetic resonance spectroscopy (mRS) of 0-2
  • Has adequate venous access
  • No planned surgical intervention except EVD
  • Written informed consent from the patient or legally authorized representative (LAR)

Who cannot take part

  • Unstable hematoma defined as > 6 mL increase as compared to previous CT volume taken at least 6 hours apart within 24 hrs after onset of ICH symptoms
  • Anticipated neurosurgical evacuation by open surgery or minimally invasive surgery with or without Alteplase (EVD allowed)
  • Used any chronic immunosuppressants or chronic anti-inflammatory drugs (excluding low-dose aspirin), by any route of administration within the past 7 days
  • Anticipated withdrawal of life-sustaining therapies within the first week after admission
  • Concomitant enrollment in another acute interventional study
  • Signs of intracranial infection or emergence of a systemic infection
  • Non-reversible bleeding diathesis
  • In the opinion of the investigator, patient has a condition that could interfere with the proposed treatment or unacceptably increase the individual's risk by participating in the study
  • Signs of liver and kidney chronic disease (i.e. creatinine >2, bilirubin > 3, receiving dialysis)
  • Uncontrolled temp >38.5˚C at enrollment
  • Is pregnant or lactating
  • In the opinion of the investigator, patient has any contraindication to the planned study assessments

Where in United States

  • University of New MexicoAlbuquerque, United States
  • Johns Hopkins HospitalBaltimore, United States
  • University of Alabama BirminghamBirmingham, United States
  • New York University Grossman School of MedicineBrooklyn, United States
  • University of CincinnatiCincinnati, United States
  • University of Texas HoustonHouston, United States
  • University of KentuckyLexington, United States
  • Yale New Haven HospitalNew Haven, United States
  • Stanford UniversityPalo Alto, United States
  • University of Texas San AntonioSan Antonio, United States
  • Cleveland Clinic FloridaStuart, United States

About the trial

What the trial wants to find out

This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH).

The 2 groups in the trial

  • ExperimentalTreatment being tested

    MW189 (0.25 mg/kg) is administered within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)

    Treatment: MW189

  • ControlPlacebo, for comparison

    Administration of saline within 24 hours of symptom onset and every 12 hours for up to 5 days (10 total doses) or until discharge (if earlier than 5 days)

    Treatment: Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Biomarker and Edema Attenuation in IntraCerebral Hemorrhage (BEACH) Phase 2a Trial
Publications
Record updated
2 April 2026